• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
PLoS One. 2010; 5(10): e13442.
Published online Oct 15, 2010. doi:  10.1371/journal.pone.0013442
PMCID: PMC2955548

E2F-1 Directly Regulates Thrombospondin 1 Expression

Jean-Marc Vanacker, Editor

Abstract

Thrombospondin 1 (TSP1) has been shown to play a critical role in inhibiting angiogenesis, resulting in inhibition of tumor growth and metastases. To figure out TSP1's regulators will lead to reveal its biological function mechanistically. In this study, we show that E2F-1 could activate the transcription of TSP1 by both promoter assays and Northern blot. Analysis of various TSP1 promoter mutant constructs showed that a sequence located −144/−137 up-stream of the transcriptional initiation site, related to the consensus E2F-responsive sequence, is necessary for the activation. In consistence with up-regulation of TSP-1 activity by over-expression of E2F-1, the knockdown of endogenous E2F-1 inhibited TSP-1 promoter activity significantly, implying that E2F-1 mediated regulation of TSP-1 is relevant in vivo. In addition, E2F-1 could also directly bind to the TSP1 promoter region covering −144/−137 region as revealed by ChIP assays. Furthermore, the E2F-1-induced activation of TSP1 gene transcription is suppressed by pRB1 in a dose-dependent manner. Taken together, the results demonstrate that TSP1 is a novel target for E2F1, which might imply that E2F-1 can affect angiogenesis by modulating TSP1 expression.

Introduction

Thrombospondin 1 (TSP1) is a large oligomeric extracellular matrix glycoprotein that mediates cell-cell and cell-matrix interactions by binding cell-surface receptors including integrins, integrin associated protein (IAP)/CD47, CD36, heparin sulfate proteoglycans, low density lipoprotein related protein 1(LRP1), and very low density lipoprotein receptor (VLDLR) in addition to other extracellular matrix proteins, and cytokines [1], [2], [3], [4], [5], [6], [7], [8], [9], [10]. As the first identified naturally occurring angiogenic inhibitor, TSP1 has been shown to play a critical role in inhibiting angiogenesis, resulting in inhibition of tumor growth and metastases [11], [12], [13], [14]. In consistence with its function in anti-angiogenesis, TSP1 could inhibit endothelial cells migration in vitro and induce endothelial cells apoptosis in vivo and in vitro [8], [9], [10], [15], [16], [17], [18], [19]. In addition, the roles of TSP1 in wound healing, ischemia, heart remodeling, foreign body reaction, intestinal inflammation and synapse formation have been recognized [20], [21], [22], [23]. The roles of TSP1 in tumor progression are closely associated with its regulation by tumor suppressors and oncogenes. Tumor suppressors including p53, PTEN and smad4 up-regulate TSP1 expression, but the oncogenes including c-jun, v-src and c-myc down-regulate TSP1 expression [12], [24], [25], [26]. Recently, the identification of gabapentin receptor α2δ-1 as a neuronal thrombospondin receptor re-enforces TSP1's role in promoting CNS (Central nervous system) synaptogenesis [27], [28], [29]. Targeted overexpression of TSP1 in mice suppressed wound healing and tumorigenesis, while lack of functional TSP1 resulted in increased vascularization of selected tissues and significantly decreased the number of excitatory synapses [13], [21], [30]. These observations further refined TSP1's major functions in vivo.

Taking advantage of cell culture system and zebrafish model, we have identified that ELL could serve as a transcriptional factor to directly up-regulate TSP1 expression [31]. ELL was first identified in acute myeloid leukemia as a translocation partner of MLL. Like other MLL translocation products, the chimera MLL-ELL appears to play an important role in leukemogenesis [32], [33], [34], [35], [36]. These findings link the TSP1 with another kind of cancer progression—leukemogenesis, unrelated to its role in anti-angiogenesis.

Although the molecular mechanisms of TSP1 in anti-angiogenesis, as well as in tumor suppression, have not been well elucidated, its regulatory factors including either activators or inhibitors seem to be accounted for acting its role. Therefore, searching for more up-stream genes of TSP1 might be helpful for uncovering its roles mechanistically.

In this study, we found that E2F-1 could transactivate TSP1 promoter activity and TSP1 promoter region contains potential E2F-1 binding consensus sequences. Using promoter assays, Northern blot and ChIP (chromatin immunoprecipitation) assays, we identified that E2F-1 could directly transactivate TSP1 expression by binding to its promoter, further expending TSP1's regulatory factors.

Materials and Methods

Cell line and plasmid construction

HEK 293 and U2OS cells were obtained from ATCC. Both cells were maintained in Dulbecco Modified Eagle Medium (Gibco) with 10% fetal bovine serum (FBS) at 37°C in a humidified atmosphere containing 5% CO2.

The cDNA of human E2F1 was amplified by PCR and cloned into the pCGN-HAM (provided by William Tansey), and pCMV-tag 2C (Stratagene) by PCR. The full length cDNA of human pRB1 was amplified by RT-PCR from cDNA pool of 293 cells and subcloned into pCGN-HAM. Deletion mutants of E2F1 were generated by PCR and cloned into pCGN-HAM, pCMV-tag 2C vectors. The TSP1 promoter (−2033 to +750) luciferase reporter was described previously [31]. Deletion mutants of the TSP1 promoter were generated by restriction endonuclease digestion or PCR and subcloned into the pGL3-Basic vector (Promega). pGL3-ARF was kindly provided by Gordon Peters. pGL3-CyclinE was kindly provided by Fred Dick. pGL3-Apaf1 was cloned from total DNA of 293 cells by PCR using primers: 5′-TATCGGTACCAACAAGGCTGGGCTGTTTCCTTCC-3′ and 5′-TATCAAGCTTTACTGGACACAAAGGGAGGAGGTCTT-3′.

To accurately map the response region of E2F1 in the TSP1 promoter, four deletion mutants (−413–0, −293–0, −173–0, −113–0) were generated by PCR and subcloned into pGL3-basic vector at KpnΙ and XhoΙ sites. The primers used for PCR were: TSP1(0)-R, 5′- GATACTCGAGGGCAAGGCGGAGGAGCCGCGCGCTTTTAAAGGG-3′; TSP1(−413)-F, 5′- ATATCGGTACCTCTAGTATCCACCTCTCGCC-3′; TSP1(−293)-F, 5′- GATAGGTACCCTTGCTGATCACCCCGAGC-3′; TSP1(−173)-F, 5′- GATAGGTACCCCCGCCCCCTTCACTTTCTA-3′; and TSP1(−113)-F, 5′- GATAGGTACCGAGCCCAGACTGGCCCCCAC-3′. To further verify E2F-1 binding sites in the promoter of TSP1, on the basis of TSP1-promoter (−393–0), a series of mutation constructs (−363-mut, −238-mut, −140-mut1, −363/−238-mut, −238/−140-mut and −363/−238/−140-mut) were generated by PCR and subcloned into pGL3-basic vector at KpnΙ and XhoΙ sites. The mutant (−140-mut2) were generated on the basis of TSP1-promoter (−173-0). All the constructs were confirmed by sequencing.

To verify E2F-1's transactivity on TSP1 promoter, an artificial E2F-1 construct was generated by PCR to clone potential E2F-1 DNA binding domain (aa110–194) into pVP16 vector (Promega) to form a fusion protein with VP16 transactivation domain (VP-16-E2F-1(110–194)). The mutant of E2F-1 deficiency in DNA binding activity (E2F-1(E132)) was generated by PCR and cloned into pCMV-tag2C vector.

To confirm whether the knock-down of E2F1 has effect on TSP-1 promoter activity, the siRNA vector targeting for human E2F1 was constructed using pSUPER according to instructions [37]. The 19-nt targeting sequence for E2F1 was 5′-TATCTGTACTACGCAGCTG-3′ [38]. U2OS cells growing 6-well plate were used for verifying E2F-1 knockdown by E2F-1 siRNA using a monoclonal antibody against E2F-1(Santa Cruz). A siRNA vector targeting GFP was used as a control.

Luciferase Reporter Assay

293 cells were grown in 24-well plates and transfected with the indicated amounts of vectors, including pTK-Renilla as an internal control, by Lipofectamine 2000. Luciferase activity was assayed 16–28 hr after transfection. The luciferase activity in cell extracts was determined by Dual-luciferase Reporter Assay System (Promega) according to the protocol supplied by the manufacturer. The relative light units were measured using a luminometer (Sirius, Zylux Corporation, Oak Ridge, TN). Data were normalized to Renilla luciferase. Data are reported as mean ± SEM of three separate experiments performed in triplicate. The statistic analysis was performed using t-test (un-paired) embedded in GraphPad Prism 5.0 Program (GraphPad Software, Inc.).

Western Blot

Anti-GAPDH and anti-E2F1 antibodies were purchased from Santa Cruz Biotechnology and Anti-HA monoclonal antibody was purchased from Covance. Anti-Flag antibody was purchased from Sigma. Western blots were performed as described previously [31]. FujiFilm LAS4000 mini luminescent image analyzer was used to photograph blots.

Northern Blot

293 cells were transfected with the pCMV-Myc empty vector (Clontech), or vectors expressing Myc-ELL. Total RNA was isolated with Trizol reagent (Invitrogen). Electrophoresis, transfer and hybridization were performed as described previously [31]. Briefly, the membrane was probed using synthesized oligos corresponding to human TSP1 (5′-acaagcaccacatttccagctgccat-3′) and human β-actin (5′-atgtgcaatcaaagtcctcggccaca-3′) labeled with biotin at the 3′ end. The signal was detected using the North2South Nucleus Labeling and Detection Kit (Pierce). Photography and data analysis were done as described for the Western blot analysis.

Chromatin Immunoprecipitation (CHIP) assay

CHIP assays were performed according to the protocol described previously [31]. Briefly, 293 cells were fixed in 1% formaldehyde and then lysed in SDS buffer. Lysates were sonicated yielding DNA fragments with an average size of 200–1000 bp and precleared with protein A/G agarose. Then lysates were immunoprecipitated by 5µg of anti-E2F1 antibody (KH95) (SC-251, Santa Cruz) or normal mouse IgG (SC-2025, Santa Cruz). Antibody–nucleoprotein complex mixtures were incubated overnight and recovered by incubation with 20µl of protein A/G agarose. Washing, elution, cross-link reversal and purification of the samples for PCR analysis were performed according to the protocol described previously. The primers specific for the TSP1 promoter region (−233/0) were: 5′- AAGGCTGCGTGGGCGGGCAC-3′ (forward) and 5′-GGCAAGGCGGAGGAGCCGCGCGC-30 (reverse). The primers specific for β-actin were described previously [31].

Results

E2F1 activates TSP1 promoter reporter effectively

When we performed experiments for verifying the specificity of TSP1 up-regulated by ELL using E2F-1 as a control, we found E2F-1 could also up-regulate TSP1 promoter reporter efficiently. In order to define the response elements in TSP1 promoter for E2F-1 up-regulation, initially, we did fine mapping for TSP1 promoter. Five deletion mutants of TSP1 promoter reporter were made by PCR and subcloned into pGL3-Basic vector (Fig. 1A). Subsequently, 6 different length TSP1 promoter reporter constructs were transfected into 293 cells together with the Renilla luciferase expression vector as an internal control in the presence of HA empty vector or HA tagged E2F-1 expression vector, a series of reporter assays were performed using Dual-luciferase Reporter Assay System (Promega) according to the protocol supplied by the manufacturer. The results showed that except for one mutant (−53–750bp), E2F-1 overexpression could activate other four TSP1 promoter significantly as revealed by statistic analysis, which suggested that E2F-1 response element was located the region between −413 to −53 (Fig. 1B). Interestingly, the TSP1 promoter reporter deleted 0–750 bp region had the highest activity stimulated by E2F-1, indicating a E2F-1 repression domain probably located in this region (0–750) (Fig. 1B). Then, we did dose response experiments for E2F-1 overexpression on TSP1 promoter activity. Flag empty vector or different dose of Flag-tagged E2F-1 expression vector, TSP1(−2033,0) promoter reporter and Renilla luciferase expression vector were co-transfected into U2OS cells. As shown in Fig. 1C, the TSP-1 promoter activity was steadily up-regulated along with increasing amounts of E2F1 expression vector. The expression of different amounts of Flag-tagged E2F1 was verified by Western blot (Fig. 1D). These results not only further confirmed the up-regulation of TSP-1 by E2F-1 effectively, but also ruled out the non-specific up-regulation of TSP-1 promoter activity as a result of ectopic expression of large amount of E2F-1 expression vector. Furthermore, to get a clear picture about the importance of E2F-1's effect on TSP-1 up-regulation, we chose three other well-known E2F-1 targeting genes' promoter luciferase reporters including ARF, Apaf1 and Cyclin E for evaluation. As judged by luciferase activity measurements, the transactivity of E2F-1 on TSP-1 promoter was lower than that of ARF, but higher than that of Cyclin E, which is similar to that of Apaf-1 (Fig. 1E). In addition, we did further fine domain mapping for the region −413 to 0 of TSP1 promoter (Fig. 1F). The results indicted that E2F-1 response elements were located in the region between −173 to −113 (Fig. 1G). The expression of HA-tagged E2F-1 (0.2µg vector/per well transfected into 293 cells growing in 6-well plate) was verified by Western blot using a monoclonal antibody against HA (Fig. 1H).

Figure 1
E2F-1 activates TSP1 promoter.

As a transcription activator, E2F1 can bind DNA cooperatively with DP proteins through the E2 recognition site (5′-TTTC[CG]CGC-3′ ) located in the promoter region of a number of genes whose products are involved in cell cycle regulation or in DNA replication [39]. After searching for the consensus sequences for E2F-1 binding, we found three potential binding sites presented in TSP1 promoter region between −363 to −137 (Fig. 2A). In order to determine whether these E2F-1 binding sites in TSP1 promoter were responsible for E2F-1 up-regulation, we made substitution mutations for the region −393 to 0 of TSP1 promoter (Fig. 2B). Then, Flag empty vector or Flag-tagged E2F1 (0.2 µg/per well in 24-well plates) was co-transfected into 293 cells along with mutant constructs and Renilla. The results from promoter assays showed that −363-mut and −238-mut could partially reverse the transcription activity of E2F1, but −140-mut almost completely reverse the transactivation of E2F1 (Fig. 2C). When the three putative binding sites were mutated simultaneously, the transactivation of TSP1 induced by E2F1 was abolished completely. In addition, the short mutant −140-mut2 also lost its responding for E2F-1 up-regulation, further confirming that the consensus binding site located between −144 to −137 was critical for E2F-1 responding.

Figure 2
E2F-1 binding site in TSP1 promoter is required for E2F-1 up-regulation.

To further test whether E2F1 DNA binding domain was critical for transactivating TSP1, the potential DNA binding domain (110–194 amino acids) was fused with VP16 activation domain using pVP16 vector (Clontech). Subsequently, we co-transfected VP16-E2F1 (110–194) (0.2 µg/per well in 24-well plates) along with TSP1 promoter luciferase reporters TSP1 (−2033 to 0 ), TSP1(−173 to 0) or TSP1 (−140-mut2 ) respectively. The luciferase assays showed that VP16-E2F1-(110–194) could indeed transactivate the TSP1 promoter reporters significantly (p<0.0001) but not TSP1 (−140-mut2) (Fig. 2E). Moreover, the E2F-1 mutant (E132) lacking DNA binding activity failed to transactivate TSP1 promoter (−2033 to 0) (Fig. 2F). These observations suggested that the DNA binding activity of E2F1 is required for inducing TSP1 expression. The expression of Flag-tagged wild-type E2F-1 and the mutant (E132) were verified by Western blot (Fig. 2G) using anti-Flag antibody. In addition, in order to test whether pRB1 could affect the transactivation of E2F-1 on TSP1 promoter, we transfected two different dosage of HA-tagged pRB1 (0.2µg and 0.5µg/per well in 24-well plates) together with HA-tagged E2F-1(0.2 µg/per well in 24-well plates) and performed promoter assays, pRB1 could indeed suppress the transactivity of E2F-1 on TSP1 promoter in a dose-dependent manner (Fig. 2H), which is consistent with the effect of pRB1 on other bona fide targets of E2F-1. At the same time, different function domains of E2F1 were cloned into Flag-tagged vector and co-transfected into 293 cells with TSP1 promoter luciferase reporter TSP1(−2033 to 0). The luciferase assay showed that only full length E2F1 can up-regulate TSP1 (−2033 to 0) (Fig. 2I). The expression of different function domains of E2F1 were verified by Western blot (Fig. 2J).

To figure out whether endogenous E2F1 could still have some influence on TSP1 promoter activity, we knocked down the expression of endogenous E2F-1 by an E2F1-specific short interfering RNA (siRNA) vector into U2OS cells. As expected, compared to the control (cells transfected with a siRNA vector specifically targeting GFP expression), E2F-1 knockdown could inhibit TSP-1 promoter (−2033, 0) activity significantly (p = 0.0001) (Fig. 2K). The knockdown of endogenous E2F1 was confirmed by Western blot (Fig. 2L). The observations suggested that E2F-1-mediated regulation of TSP-1 is physiologic relevant.

E2F1 binds to the TSP1 promoter in vivo

To demonstrate whether the action of E2F1 on TSP1 occurs in vivo, we conducted chromatin Immunoprecipitation assay to test the binding of E2F1 in the TSP1 promoter. As shown in Fig. 3B, an enrichment of the TSP1 promoter was detected using anti-E2F1 antibody in 293 cells. No signal was observed using a negative control antibody (normal mouse IgG). Primers specific for β-actin was used as control. These results indicated that E2F1 could bind to the TSP1 promoter directly in 293 cells.

Figure 3
E2F-1 directly binds to TSP1 promoter.

E2F1 up-regulates TSP1 mRNA expression

We next want to test whether E2F1 could up-regulate expression of the endogenous TSP1 gene. Total RNA was extracted from 293 cells 24h after transfected by either HA-E2F1 expression vector or equivalent control empty vector. Up-regulation of TSP1 mRNA by E2F1 was confirmed by Northern blot analysis (Fig. 4) which suggested that E2F1 could indeed induce TSP1 mRNA expression.

Figure 4
E2F-1 up-regulates TSP1 mRNA expression.

Discussion

In this study, through domain mapping for TSP1 promoter, we identified that the E2F-1 binding consensus sequence located in −144 to −137 of TSP1 promoter is critical for E2F1 up-regulation. Further ChIP assays confirmed that E2F-1 could bind the promoter region covering −144 to −137 in vivo. These observations suggested that E2F-1 could regulate TSP1 expression by directly binding to its promoter. In addition, we verified that the DNA binding domain and DNA binding ability of E2F-1 were required for transactivating TSP1 expression. Furthermore, we found that the knockdown of endogenous E2F-1 could inhibit TSP-1 promoter activity significantly, confirming the relevance of E2F-1 mediated regulation of TSP-1 in vivo. Taken together, these results suggested that TSP1 is a direct target of E2F-1.

E2F-1 belongs to a large family of transcription factors containing one or more conserved DNA binding domains (DBDs) that bind target promoters and regulate their expression [40], [41], [42]. To elucidate E2F-1's function, searching for E2F-1's bona fide targets has been extensively conducted. Through global gene expression profiling and promoter occupancy arrays, many target genes of E2F-1 being critical for proper cell cycle progression have been identified, which established a direct role for E2F-1 in governing cell proliferation [41], [43], [44]. Moreover, the roles of E2F-1 in cancer have been well-recognized due to its association with pRB1— a classic tumor suppressor. The pRB1 tumor suppressor directly associates with E2F-1 to modulate gene expression, either inhibit its transactivation or enhance its suppressive function [43], [44], [45], [46]. Functional inactivation of pRB1 in various human cancers leads to deregulated E2F1 activity [46]. Here, we presented data to show that pRB1 could also suppress E2F-1's transactivity on TSP1 promoter in a dose-dependent manner, which is consistent with the role of pRB1 in modulating expression of E2F-1 targets, further confirming that TSP1 serves as a bona fide target of E2F-1.

The role of genes in anti-angiogenesis represents a major aspect for their function in tumor suppression [47]. Even though, the roles of E2F-1 in tumor progression have been extensively investigated, however, to date, little is known about its function relevant to angiogenesis. TSP1 is the first identified naturally occurring angiogenic inhibitor, its role in inhibiting angiogenesis, resulting in inhibition of tumor growth and metastases has been well-defined [11], and therefore, the identification of TSP1 as a direct target of E2F-1 might open a new window for demonstrating the role of E2F-1 on anti-angiogenesis, relevant to its function in tumor suppression. Of cause, how E2F-1 acting its role in anti-angiogenesis through the regulation of TSP1 expression is definitely worth to be further investigated.

Acknowledgments

We are grateful to Drs. Olga Volpert, Fred Dick, Gordon Peters and William Tansey for the generous gift of reagents.

Footnotes

Competing Interests: The authors have declared that no competing interests exist.

Funding: W.X. is supported by “973” grant 2010CB126306, 2007CB815705, 2006CB504102, Natural Science Foundation of China (NSFC) grant 31071211, 30971667, 30890113 and National Transgene Project 2009ZX08010-021B. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Bein K, Simons M. Thrombospondin type 1 repeats interact with matrix metalloproteinase 2. Regulation of metalloproteinase activity. J Biol Chem. 2000;275:32167–32173. [PubMed]
2. Dawson DW, Pearce SF, Zhong R, Silverstein RL, Frazier WA, et al. CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol. 1997;138:707–717. [PMC free article] [PubMed]
3. Greenaway J, Lawler J, Moorehead R, Bornstein P, Lamarre J, et al. Thrombospondin-1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor-related protein-1 (LRP-1). J Cell Physiol. 2007;210:807–818. [PMC free article] [PubMed]
4. Isenberg JS, Jia Y, Fukuyama J, Switzer CH, Wink DA, et al. Thrombospondin-1 inhibits nitric oxide signaling via CD36 by inhibiting myristic acid uptake. J Biol Chem. 2007;282:15404–15415. [PMC free article] [PubMed]
5. Isenberg JS, Ridnour LA, Dimitry J, Frazier WA, Wink DA, et al. CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1. J Biol Chem. 2006;281:26069–26080. [PubMed]
6. Krutzsch HC, Choe BJ, Sipes JM, Guo N, Roberts DD. Identification of an alpha(3)beta(1) integrin recognition sequence in thrombospondin-1. J Biol Chem. 1999;274:24080–24086. [PubMed]
7. Li Z, Calzada MJ, Sipes JM, Cashel JA, Krutzsch HC, et al. Interactions of thrombospondins with alpha4beta1 integrin and CD47 differentially modulate T cell behavior. J Cell Biol. 2002;157:509–519. [PMC free article] [PubMed]
8. Moodley Y, Rigby P, Bundell C, Bunt S, Hayashi H, et al. Macrophage recognition and phagocytosis of apoptotic fibroblasts is critically dependent on fibroblast-derived thrombospondin 1 and CD36. Am J Pathol. 2003;162:771–779. [PMC free article] [PubMed]
9. Oganesian A, Armstrong LC, Migliorini MM, Strickland DK, Bornstein P. Thrombospondins use the VLDL receptor and a nonapoptotic pathway to inhibit cell division in microvascular endothelial cells. Mol Biol Cell. 2008;19:563–571. [PMC free article] [PubMed]
10. Pallero MA, Elzie CA, Chen J, Mosher DF, Murphy-Ullrich JE. Thrombospondin 1 binding to calreticulin-LRP1 signals resistance to anoikis. Faseb J. 2008;22:3968–3979. [PMC free article] [PubMed]
11. Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci U S A. 1990;87:6624–6628. [PMC free article] [PubMed]
12. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science. 1994;265:1582–1584. [PubMed]
13. Liu P, Wang Y, Li YH, Yang C, Zhou YL, et al. Adenovirus-mediated gene therapy with an antiangiogenic fragment of thrombospondin-1 inhibits human leukemia xenograft growth in nude mice. Leuk Res. 2003;27:701–708. [PubMed]
14. Rodriguez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J, et al. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci U S A. 2001;98:12485–12490. [PMC free article] [PubMed]
15. Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, et al. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med. 2000;6:41–48. [PubMed]
16. Li K, Yang M, Yuen PM, Chik KW, Li CK, et al. Thrombospondin-1 induces apoptosis in primary leukemia and cell lines mediated by CD36 and Caspase-3. Int J Mol Med. 2003;12:995–1001. [PubMed]
17. Sheibani N, Frazier WA. Repression of thrombospondin-1 expression, a natural inhibitor of angiogenesis, in polyoma middle T transformed NIH3T3 cells. Cancer Lett. 1996;107:45–52. [PubMed]
18. Brechot N, Gomez E, Bignon M, Khallou-Laschet J, Dussiot M, et al. Modulation of macrophage activation state protects tissue from necrosis during critical limb ischemia in thrombospondin-1-deficient mice. PLoS One. 2008;3:e3950. [PMC free article] [PubMed]
19. Bruel A, Touhami-Carrier M, Thomaidis A, Legrand C. Thrombospondin-1 (TSP-1) and TSP-1-derived heparin-binding peptides induce promyelocytic leukemia cell differentiation and apoptosis. Anticancer Res. 2005;25:757–764. [PubMed]
20. Kyriakides TR, Maclauchlan S. The role of thrombospondins in wound healing, ischemia, and the foreign body reaction. J Cell Commun Signal. 2009;3:215–225. [PMC free article] [PubMed]
21. Agah A, Kyriakides TR, Lawler J, Bornstein P. The lack of thrombospondin-1 (TSP1) dictates the course of wound healing in double-TSP1/TSP2-null mice. Am J Pathol. 2002;161:831–839. [PMC free article] [PubMed]
22. DiPietro LA, Nissen NN, Gamelli RL, Koch AE, Pyle JM, et al. Thrombospondin 1 synthesis and function in wound repair. Am J Pathol. 1996;148:1851–1860. [PMC free article] [PubMed]
23. Streit M, Velasco P, Riccardi L, Spencer L, Brown LF, et al. Thrombospondin-1 suppresses wound healing and granulation tissue formation in the skin of transgenic mice. Embo J. 2000;19:3272–3282. [PMC free article] [PubMed]
24. Wen S, Stolarov J, Myers MP, Su JD, Wigler MH, et al. PTEN controls tumor-induced angiogenesis. Proc Natl Acad Sci U S A. 2001;98:4622–4627. [PMC free article] [PubMed]
25. Watnick RS, Cheng YN, Rangarajan A, Ince TA, Weinberg RA. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell. 2003;3:219–231. [PubMed]
26. Lawler J, Miao WM, Duquette M, Bouck N, Bronson RT, et al. Thrombospondin-1 gene expression affects survival and tumor spectrum of p53-deficient mice. Am J Pathol. 2001;159:1949–1956. [PMC free article] [PubMed]
27. Eroglu C, Allen NJ, Susman MW, O'Rourke NA, Park CY, et al. Gabapentin receptor alpha2delta-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis. Cell. 2009;139:380–392. [PMC free article] [PubMed]
28. Christopherson KS, Ullian EM, Stokes CC, Mullowney CE, Hell JW, et al. Thrombospondins are astrocyte-secreted proteins that promote CNS synaptogenesis. Cell. 2005;120:421–433. [PubMed]
29. Xu J, Xiao N, Xia J. Thrombospondin 1 accelerates synaptogenesis in hippocampal neurons through neuroligin 1. Nat Neurosci. 13:22–24. [PubMed]
30. Wang S, Wu Z, Sorenson CM, Lawler J, Sheibani N. Thrombospondin-1-deficient mice exhibit increased vascular density during retinal vascular development and are less sensitive to hyperoxia-mediated vessel obliteration. Dev Dyn. 2003;228:630–642. [PubMed]
31. Zhou J, Feng X, Ban B, Liu J, Wang Z, et al. Elongation factor ELL (Eleven-Nineteen Lysine-rich Leukemia) acts as a transcription factor for direct thrombospondin-1 regulation. J Biol Chem. 2009;284:19142–19152. [PMC free article] [PubMed]
32. Armstrong SA, Staunton JE, Silverman LB, Pieters R, den Boer ML, et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet. 2002;30:41–47. [PubMed]
33. Eguchi M, Eguchi-Ishimae M, Greaves M. Molecular pathogenesis of MLL-associated leukemias. Int J Hematol. 2005;82:9–20. [PubMed]
34. Liu H, Takeda S, Cheng EH, Hsieh JJ. Biphasic MLL takes helm at cell cycle control: implications in human mixed lineage leukemia. Cell Cycle. 2008;7:428–435. [PubMed]
35. Thirman MJ, Levitan DA, Kobayashi H, Simon MC, Rowley JD. Cloning of ELL, a gene that fuses to MLL in a t(11;19)(q23;p13.1) in acute myeloid leukemia. Proc Natl Acad Sci U S A. 1994;91:12110–12114. [PMC free article] [PubMed]
36. DiMartino JF, Miller T, Ayton PM, Landewe T, Hess JL, et al. A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL. Blood. 2000;96:3887–3893. [PubMed]
37. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science. 2002;296:550–553. [PubMed]
38. Liu K, Luo Y, Lin FT, Lin WC. TopBP1 recruits Brg1/Brm to repress E2F1-induced apoptosis, a novel pRb-independent and E2F1-specific control for cell survival. Genes Dev. 2004;18:673–686. [PMC free article] [PubMed]
39. Helin K, Wu CL, Fattaey AR, Lees JA, Dynlacht BD, et al. Heterodimerization of the transcription factors E2F-1 and DP-1 leads to cooperative trans-activation. Genes Dev. 1993;7:1850–1861. [PubMed]
40. Attwooll C, Lazzerini Denchi E, Helin K. The E2F family: specific functions and overlapping interests. Embo J. 2004;23:4709–4716. [PMC free article] [PubMed]
41. Chen HZ, Tsai SY, Leone G. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer. 2009;9:785–797. [PMC free article] [PubMed]
42. Harbour JW, Dean DC. The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev. 2000;14:2393–2409. [PubMed]
43. Frolov MV, Dyson NJ. Molecular mechanisms of E2F-dependent activation and pRB-mediated repression. J Cell Sci. 2004;117:2173–2181. [PubMed]
44. van den Heuvel S, Dyson NJ. Conserved functions of the pRB and E2F families. Nat Rev Mol Cell Biol. 2008;9:713–724. [PubMed]
45. Nevins JR. The Rb/E2F pathway and cancer. Hum Mol Genet. 2001;10:699–703. [PubMed]
46. Burkhart DL, Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer. 2008;8:671–682. [PubMed]
47. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008;8:579–591. [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science
PubReader format: click here to try

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

Links

Recent Activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...